Research programme: Bruton's tyrosine kinase inhibitors - CGI PharmaceuticalsAlternative Names: Btk inhibitors research programme - CGI Pharmaceuticals
Latest Information Update: 06 Sep 2010
At a glance
- Originator CGI Pharmaceuticals
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 06 Sep 2010 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 06 Sep 2010 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
- 25 Jul 2007 This programme is still in active development